JPMorgan Chase & Co. Boosts Cencora (NYSE:COR) Price Target to $417.00

Cencora (NYSE:COR) had its target price lifted by analysts at JPMorgan Chase & Co. from $344.00 to $417.00 in a report issued on Tuesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 14.64% from the company’s current price.

Other analysts have also issued reports about the company. TD Cowen increased their target price on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a report on Monday. Evercore ISI set a $400.00 target price on shares of Cencora and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Morgan Stanley set a $330.00 price target on Cencora and gave the stock an “equal weight” rating in a report on Wednesday, July 16th. Weiss Ratings restated a “buy (b-)” rating on shares of Cencora in a report on Thursday, October 30th. Finally, Wall Street Zen upgraded shares of Cencora from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Cencora has a consensus rating of “Moderate Buy” and an average target price of $371.09.

Cencora Trading Down 0.4%

Shares of NYSE:COR opened at $363.75 on Tuesday. The business has a 50 day moving average of $318.52 and a 200-day moving average of $301.12. The stock has a market cap of $70.52 billion, a PE ratio of 37.42, a P/E/G ratio of 1.56 and a beta of 0.63. Cencora has a 12-month low of $223.92 and a 12-month high of $366.17. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. During the same quarter last year, the business earned $3.34 EPS. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, equities research analysts forecast that Cencora will post 15.37 earnings per share for the current year.

Insider Buying and Selling

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the sale, the chief executive officer owned 37,940 shares in the company, valued at approximately $12,398,792. This trade represents a 11.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman directly owned 305,913 shares in the company, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 41,544 shares of company stock valued at $12,230,941 in the last ninety days. 10.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Cencora

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Cornerstone Wealth Group LLC grew its stake in shares of Cencora by 1.3% in the 3rd quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company’s stock worth $745,000 after buying an additional 30 shares during the last quarter. Security Financial Services INC. grew its position in Cencora by 2.6% in the 3rd quarter. Security Financial Services INC. now owns 1,325 shares of the company’s stock worth $414,000 after purchasing an additional 33 shares during the period. Atlantic Edge Private Wealth Management LLC grew its holdings in shares of Cencora by 70.0% in the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after acquiring an additional 35 shares during the period. Hemington Wealth Management raised its holdings in Cencora by 12.0% during the third quarter. Hemington Wealth Management now owns 327 shares of the company’s stock valued at $102,000 after acquiring an additional 35 shares during the period. Finally, Obermeyer Wealth Partners grew its position in shares of Cencora by 1.3% during the first quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company’s stock worth $758,000 after purchasing an additional 36 shares in the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.